Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cogent Biosciences

Request full access

Developing precision therapies for genetically defined diseases

Cambridge, United StatesFounded 2014Biotech & Life Sciences

About Cogent Biosciences

Cogent Biosciences is a biotechnology company focused on the discovery and development of innovative small molecule therapies targeting rare, genetically driven diseases. The company serves patients with unmet medical needs, particularly those suffering from conditions that have limited treatment options. Operating within the biopharmaceutical market, Cogent Biosciences employs a research-driven business model, leveraging its scientific expertise to advance drug candidates through clinical trials. Revenue is primarily generated through the development and potential commercialization of these therapies, as well as through strategic partnerships and collaborations. The company has a strong financial position, with a year-end cash reserve of $242.2 million, supporting its ongoing research and development activities. Key initiatives include three clinical trials for their lead candidate, CGT9486, set to commence this year.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2018

Cogent Biosciences in the Cambridge ecosystem

Live from Dealroom

The Cogent Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

19 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

  • New Leaf Venture Partners
  • Wellington Management
  • Seagen
  • Sectoral Asset Management
  • Novo Seeds
  • F-Prime
  • Cowen Group
  • Jennison Associates
  • Sanofi Ventures

Series B and later10 investors entered at this stage

Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$95k

3 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Cogent Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.